Voyager Therapeutics (VYGR) Non Operating Income (2015 - 2026)

Voyager Therapeutics has disclosed Non Operating Income across 12 years of filings, most recently posting $1.9 million for Q2 2026.

• In Q2 2026, Non Operating Income fell 40.48% year-over-year to $1.9 million; the TTM figure through Jun 2026 stood at $9.6 million (down 40.61% YoY), while the FY2025 annual figure was $12.3 million, down 35.27% from the prior year.
• Non Operating Income came in at $1.9 million for Q2 2026 at Voyager Therapeutics, down from $2.3 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $4.9 million in Q2 2024 to a low of $31000.0 in Q1 2022.
• Average Non Operating Income over 5 years is $2.9 million, with a median of $3.2 million recorded in 2022.
• The largest YoY upside for Non Operating Income was 35255.56% in 2022 against a maximum downside of 99.21% in 2022.
• Over 5 years, Non Operating Income stood at $953000.0 in 2022, then soared by 230.95% to $3.2 million in 2023, then jumped by 39.38% to $4.4 million in 2024, then plunged by 42.79% to $2.5 million in 2025, then retreated by 22.9% to $1.9 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were $1.9 million in Q2 2026, $2.3 million in Q1 2026, and $2.5 million in Q4 2025.